Capacity Challenges Prompt NICE To Consider Secondees From Consultancy Firms
England’s health technology assessment institute is exploring solutions to help deal with its increased workload, high staff turnover and challenges in recruiting people with the expertise needed.
You may also be interested in...
Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.
An alliance of blood cancer charities has called for multi-indication and combination pricing to be introduced in the UK as part of a future pricing and access deal. The group also requested a transparent and formal way of involving patients as the government and industry negotiate a successor to the Voluntary Scheme for Branded Medicines Pricing and Access, which is due to end in 2023.
Uncertainty over the payments that will be due from companies to manage the branded medicines bill in 2023 and beyond has been a cause for concern for firms, which last month had to decide whether to remain in or exit the Voluntary Scheme for Branded Medicines Pricing and Access. If many companies have left, the “remainers” might end up paying more than their fair share, though the government has offered some assurance on this front.